CN114452314A - Albendazole ivermectin powder and preparation method thereof - Google Patents
Albendazole ivermectin powder and preparation method thereof Download PDFInfo
- Publication number
- CN114452314A CN114452314A CN202210034051.0A CN202210034051A CN114452314A CN 114452314 A CN114452314 A CN 114452314A CN 202210034051 A CN202210034051 A CN 202210034051A CN 114452314 A CN114452314 A CN 114452314A
- Authority
- CN
- China
- Prior art keywords
- parts
- albendazole
- ivermectin
- powder
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 title claims abstract description 85
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 title claims abstract description 85
- 229960002418 ivermectin Drugs 0.000 title claims abstract description 85
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 229960002669 albendazole Drugs 0.000 title claims abstract description 76
- 239000000843 powder Substances 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000314 lubricant Substances 0.000 claims abstract description 29
- 239000003381 stabilizer Substances 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 239000000796 flavoring agent Substances 0.000 claims abstract description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 13
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims description 38
- 239000000463 material Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 238000002844 melting Methods 0.000 claims description 12
- 230000008018 melting Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 238000004945 emulsification Methods 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 6
- 229920002261 Corn starch Polymers 0.000 claims description 5
- 239000008120 corn starch Substances 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001509 sodium citrate Substances 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- 229920001592 potato starch Polymers 0.000 claims description 4
- 229940085605 saccharin sodium Drugs 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 101100273639 Carassius auratus ccna1 gene Proteins 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 229940057948 magnesium stearate Drugs 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 15
- 241001465754 Metazoa Species 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 235000019629 palatability Nutrition 0.000 abstract description 6
- 241001061264 Astragalus Species 0.000 abstract description 3
- 208000035240 Disease Resistance Diseases 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 235000006533 astragalus Nutrition 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 3
- 210000004233 talus Anatomy 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000000749 insecticidal effect Effects 0.000 abstract description 2
- 238000005461 lubrication Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000006870 function Effects 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 6
- 241000244206 Nematoda Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000238876 Acari Species 0.000 description 3
- 230000000507 anthelmentic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000005660 Abamectin Substances 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- VXTGHWHFYNYFFV-LJQANCHMSA-N (R)-albendazole S-oxide Chemical compound CCC[S@@](=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-LJQANCHMSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000500916 Corydalidae Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000509427 Sarcoptes scabiei Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229950010102 albendazole oxide Drugs 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000835 effect on nematodes Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001213 vestibule labyrinth Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses albendazole ivermectin powder and a preparation method thereof, belonging to the technical field of veterinary medicines and comprising the following raw materials in parts by weight: 15-20 parts of albendazole, 0.5-1.5 parts of ivermectin, 8-13 parts of lubricant, 70-100 parts of disintegrating agent, 5-8 parts of stabilizer, 2-6 parts of flavoring agent, 3-8 parts of astragalus extract and 3-8 parts of liquorice. The invention also discloses a preparation method. The albendazole/ivermectin powder provided by the invention has the advantages that the stability and the dispersibility of albendazole and ivermectin are remarkably improved, the albendazole/ivermectin powder has the effects of lubrication, adhesion resistance and flow aid, the dissolution and absorption of albendazole/ivermectin powder are accelerated, and the function is played. Meanwhile, the palatability of albendazole ivermectin powder can be improved, the insecticidal effect is improved, and the food calling function is increased. The addition of the astragalus and the liquorice can not only tonify the deficiency of animal substances, enhance the activity function, improve the disease resistance and eliminate the weak symptoms, but also can be used for harmonizing the drug properties, reducing the toxic and side effects and improving the palatability.
Description
Technical Field
The invention relates to the technical field of veterinary drugs, and in particular relates to albendazole ivermectin powder and a preparation method thereof.
Background
The ivermectin albendazole powder is a compound anthelmintic consisting of ivermectin and albendazole. Wherein the ivermectin is avermectin (Avermectins) and has strong killing effect on most nematodes and arthropods. Researches find that the ivermectin has good expelling effect on nematodes in families of trichosanthis, circulaceae, retrocirculaceae, corydalidae, ascariaceae, pteridae, filariaceae, cephalanoploidae, sipunculaceae, dictyodaceae and the like of livestock, some are effective on adult stages, some are effective on larva stages, and some are effective on the whole development stage; the ivermectin also has a high killing effect on a plurality of fourth-stage larvae of nematodes which can not be killed by the anthelmintic and reside in tissues for a long time. Parasites which have drug resistance to other anthelmintics are also sensitive to ivermectin, and are not prone to developing drug resistance to ivermectin. Ivermectin is most commonly applied to arthropod pests, has better effects on cattle and sheep nosebleed diseases, scabies and mites of various domestic animals, itch mites, blood lice and poultry knee mites, and has moderate killing effect on hair lice; ivermectin can prevent the vital activities of blood sucking, molting, reproduction and the like of ticks. The ivermectin insect expelling mechanism acts on GABA receptors of parasitic neuron synapses or neuromuscular synapses, interferes with information transmission of nerve endings in insects, and finally causes paralysis and death of the insects, so that the ivermectin insect expelling mechanism has little or no active effect on flat animals, bacteria, actinomycetes and the like without GABA transmitters in the bodies. The albendazole not only has high efficiency on various nematodes, but also has strong expelling effect on some trematodes and tapeworms; has effects of completely killing hookworm egg and whipworm egg and partially killing roundworm egg. The action mechanism of the drug is that the drug selectively and irreversibly inhibits the polymerization of a plasmocyte microtubule system of intestinal wall cells of the intestinal nematodes, blocks the uptake and absorption of the intestinal nematodes on various nutrients and glucose, leads to the exhaustion of endogenous glycogen of the larvae, inhibits a fumarate reductase system, prevents the generation of adenosine triphosphate, and leads to the incapability of survival and reproduction of the larvae; meanwhile, the cell plasma microtubules of intestinal cells of the polypide can also be denatured and combined with tubulin of the intestinal cells to cause the transportation and blockage of cells, so that secretory granules in Golgi bodies are accumulated, the cytoplasm is gradually dissolved, and absorption cells are completely denatured to cause the polypide to die.
Practice proves that the ivermectin and albendazole are combined to prepare the ivermectin albendazole powder, so that the defects of the two medicines in an insect-resistant spectrum can be overcome, the insect-resistant spectrum is wider, the efficiency is higher, and the trouble of multiple administration for expelling various parasites by people is relieved. However, it has been found in actual production that ivermectin albendazole oxide powder is difficult to mix uniformly during preparation, the finished product is difficult to administer to large groups of animals, and it is difficult or impossible to mix uniformly with feed. Therefore, in clinical application, the animals often have poor curative effects or side effects or even toxicities due to non-uniform drug intake. When animals expel parasites, the animals usually suffer from body material deficiency, the activity function is weakened, and the disease resistance is reduced.
At present, the existing preparation method of albendazole ivermectin powder mainly has the following problems: the ivermectin has small feeding dose and is not easy to be mixed uniformly; the powder has fluidity, so that the active ingredients in the product are not uniformly distributed during production; albendazole is extremely insoluble, is easy to agglomerate after being mixed with general auxiliary materials, and is difficult to disperse when mixed with feed; the need for invigoration of the animal body is not considered.
Disclosure of Invention
The invention aims to provide albendazole ivermectin powder and a preparation method thereof, and aims to solve the problems in the prior art.
In order to achieve the purpose, the invention provides the following scheme:
the invention provides albendazole ivermectin powder which is characterized in that: the albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 15-20 parts of albendazole, 0.5-1.5 parts of ivermectin, 8-13 parts of lubricant, 70-100 parts of disintegrating agent, 5-8 parts of stabilizer, 2-6 parts of flavoring agent, 3-8 parts of astragalus extract and 3-8 parts of liquorice.
In the albendazole ivermectin powder, as a preferable scheme, the albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 16-18 parts of albendazole, 0.8-1.2 parts of ivermectin, 10-12 parts of lubricant, 80-90 parts of disintegrating agent, 6-8 parts of stabilizer, 3-5 parts of flavoring agent, 4-6 parts of astragalus extract and 5-7 parts of liquorice.
In the albendazole/ivermectin powder, the lubricant is preferably one or more of magnesium stearate, polyethylene glycol 4000, polyethylene glycol 6000, talcum powder and hydrogenated vegetable oil.
In the albendazole ivermectin powder, the disintegrating agent is preferably one or more of corn starch, potato starch, sodium carboxymethyl starch, low-substituted cellulose, cross-linked PVP and cross-linked CCNa.
In the albendazole ivermectin powder, the stabilizer is one or more of sodium citrate and xanthan gum.
In the albendazole ivermectin powder, the flavoring agent is preferably one or more of powdered sugar, saccharin sodium and sucrose.
The second scheme of the invention provides a preparation method of the albendazole ivermectin powder, which comprises the following steps:
(1) weighing the raw materials according to the weight parts, crushing and sieving the materials;
(2) after the lubricant is heated and melted uniformly while stirring, adding the disintegrant while stirring, and adding the ivermectin after complete melting for continuous emulsification;
(3) continuously adding albendazole into the mixture obtained in the step (2), and uniformly stirring;
(4) continuously adding radix astragali extract and Glycyrrhrizae radix, stirring, adding stabilizer and correctant, mixing, and stirring.
In the preparation method of albendazole ivermectin powder, as a preferable scheme, the powder crushed in the step (1) is sieved by a 250-mesh and 300-mesh sieve.
In the above method for preparing albendazole ivermectin powder, preferably, the heating temperature in the step (2) is 85-105 ℃.
In the preparation method of albendazole ivermectin powder, as a preferable scheme, the stirring time in each preparation process is 15-20 min.
Compared with the prior art, the invention has the following technical effects:
the albendazole ivermectin powder provided by the invention has the advantages that the stability and the dispersibility of albendazole and ivermectin are obviously improved by optimizing the relation of the raw material composition ratio of the albendazole ivermectin powder and the addition of the lubricant disintegrant, and the albendazole and ivermectin powder has the functions of lubrication, adhesion resistance and flow aid, and is accelerated to be dissolved and absorbed to play a role. Meanwhile, the palatability of albendazole ivermectin powder can be improved, the insecticidal effect is improved, and the food calling function is increased. Solves the problem of uneven dispersion of albendazole ivermectin powder, and improves the fluidity and the dispersibility of the pharmaceutical preparation.
In addition, the invention also adds two Chinese herbal medicines, astragalus and liquorice. Radix astragali has effects of invigorating qi, invigorating yang, consolidating superficial resistance, arresting sweating, inducing diuresis, relieving swelling, promoting fluid production, nourishing blood, removing stagnation, relieving arthralgia, removing toxic substance, expelling pus, healing sore, and promoting granulation; has promoting effect and function on nucleic acid metabolism; enhancing hematopoietic function; improving myocardial function, and resisting myocardial infarction; has antioxidant, antiviral, anticancer, renal function improving, and renal histopathological changes improving effects. The liquorice has the efficacies of invigorating spleen and replenishing qi, relieving cough and eliminating phlegm, relieving spasm and relieving pain and harmonizing drug property; has adrenocortical hormone action, antiinflammatory, antiulcer, antiallergic, anticancer, antibacterial, antiviral, pancreatic secretion promoting, in vitro intestine inhibiting, immunity regulating, cough relieving, phlegm eliminating, mutation resisting, toxic substance removing, antioxidant, ear vestibule function protecting, diuretic, liver protecting, arteriosclerosis preventing, cerebral ischemia resisting, and diabetes complication preventing effects. The astragalus and the liquorice are added to tonify the deficiency of animal substances, enhance the activity function, improve the disease resistance and eliminate the weak symptoms, and can be used for harmonizing the drug property, lightening the toxic and side effects and improving the palatability.
The flavoring agent added into the albendazole ivermectin powder provided by the invention has the characteristic of sweetening, so that the bitter taste and the astringent taste in the medicine can be covered, the flavor is improved, and the palatability of the medicine can be improved; the stability of the medicine can be improved by adding the stabilizer.
The preparation method of albendazole ivermectin powder provided by the invention is convenient for uniform mixing and ensures the stability of the powder; can ensure the uniform particle size of the powder and improve the stability and the dispersibility. The preparation process is simple, the production cost is low, and the method is suitable for industrial mass production.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The specification and examples are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
Example 1
The albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 15 parts of albendazole, 0.5 part of ivermectin, 8 parts of lubricant, 70 parts of disintegrating agent, 5 parts of stabilizer, 2 parts of flavoring agent, 3 parts of astragalus extract and 3 parts of liquorice. Wherein the lubricant is magnesium stearate; the disintegrating agent is corn starch and sodium carboxymethyl cellulose in a mass ratio of 5: 1, mixing; the stabilizer is sodium citrate; the correctant is sucrose.
The preparation method comprises the following steps:
(1) weighing the raw materials according to the weight parts, crushing the materials, and sieving the crushed materials with a 250-mesh sieve;
(2) heating the lubricant to 85 ℃ while stirring for melting uniformly, continuously stirring for 15min while adding the disintegrant, and adding the ivermectin after complete melting for continuous emulsification;
(3) continuously adding albendazole into the mixture obtained in the step (2), and uniformly stirring for 15 min;
(4) continuously adding radix astragali extract and Glycyrrhrizae radix, stirring for 15min, adding stabilizer and correctant, mixing and stirring for 15min to obtain the final product.
Example 2
The albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 20 parts of albendazole, 1.5 parts of ivermectin, 13 parts of lubricant, 100 parts of disintegrating agent, 8 parts of stabilizer, 6 parts of flavoring agent, 8 parts of astragalus extract and 8 parts of liquorice. Wherein, the lubricant is polyethylene glycol 4000 and polyethylene glycol 6000 according to the weight ratio of 1: 1, mixing the components in a mass ratio; the disintegrating agent is cross-linked PVP and cross-linked CCNa according to the mass ratio of 1: 1, mixing; the stabilizer is xanthan gum; the correctant is sugar powder.
The preparation method comprises the following steps:
(1) weighing the raw materials according to the weight parts, crushing the materials, and sieving the crushed materials with a 300-mesh sieve;
(2) heating the lubricant to 105 ℃ while stirring for melting uniformly, continuously stirring for 20min while adding the disintegrant, and adding the ivermectin after complete melting for continuous emulsification;
(3) continuously adding albendazole into the mixture obtained in the step (2), and uniformly stirring for 20 min;
(4) continuously adding radix astragali extract and Glycyrrhrizae radix, stirring for 15min, adding stabilizer and correctant, mixing and stirring for 20min to obtain the final product.
Example 3
The albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 16 parts of albendazole, 0.8 part of ivermectin, 10 parts of lubricant, 80 parts of disintegrating agent, 6 parts of stabilizer, 3 parts of flavoring agent, 4 parts of astragalus extract and 5 parts of liquorice. Wherein, the lubricant is talcum powder and hydrogenated vegetable oil, and the weight ratio of the talcum powder to the hydrogenated vegetable oil is 5: 1, mixing the components in a mass ratio; the disintegrating agent is potato starch and low-substituted cellulose in a mass ratio of 3: 1, mixing; the stabilizer is sodium citrate; the correctant is saccharin sodium.
The preparation method comprises the following steps:
(1) weighing the raw materials according to the weight parts, crushing the materials, and sieving the crushed materials through a 270-mesh sieve;
(2) heating the lubricant to 90 ℃ while stirring for melting uniformly, continuously stirring for 16min while adding the disintegrant, and adding the ivermectin after complete melting for continuous emulsification;
(3) continuously adding albendazole into the mixture obtained in the step (2), and uniformly stirring for 16 min;
(4) continuously adding radix astragali extract and Glycyrrhrizae radix, stirring for 15min, adding stabilizer and correctant, mixing and stirring for 16min to obtain the final product.
Example 4
The albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 18 parts of albendazole, 1.2 parts of ivermectin, 12 parts of lubricant, 90 parts of disintegrating agent, 8 parts of stabilizer, 5 parts of flavoring agent, 6 parts of astragalus extract and 7 parts of liquorice. Wherein, the lubricant is magnesium stearate, talcum powder and hydrogenated vegetable oil, and the weight ratio of the lubricant to the lubricant is 3: 1: 2, mixing the components in a mass ratio; the disintegrating agent is corn starch and potato starch in a mass ratio of 1: 1, mixing; the stabilizer is xanthan gum; the flavoring agent is sucrose and powdered sugar according to the weight ratio of 1: 1 mass ratio.
The preparation method comprises the following steps:
(1) weighing the raw materials according to the weight parts, crushing the materials, and sieving the crushed materials with a 290-mesh sieve;
(2) heating the lubricant to 100 ℃ while stirring for melting uniformly, continuously stirring for 18min while adding the disintegrant, and adding the ivermectin after complete melting for continuous emulsification;
(3) continuously adding albendazole into the mixture obtained in the step (2), and uniformly stirring for 18 min;
(4) continuously adding radix astragali extract and Glycyrrhrizae radix, stirring for 18min, adding stabilizer and correctant, mixing and stirring for 18min to obtain the final product.
Example 5
The albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 17 parts of albendazole, 1.0 part of ivermectin, 11 parts of lubricant, 85 parts of disintegrating agent, 7 parts of stabilizer, 4 parts of flavoring agent, 5 parts of astragalus extract and 6 parts of liquorice. Wherein, the lubricant is magnesium stearate, polyethylene glycol 4000, polyethylene glycol 6000 and hydrogenated vegetable oil, and the weight ratio of the lubricant to the lubricant is 3: 1: 1: 1, mixing the components in a mass ratio; the disintegrating agent is corn starch and cross-linked PVP (polyvinyl pyrrolidone) in a mass ratio of 1: 1, mixing; the stabilizer is sodium citrate; the correctant is saccharin sodium.
The preparation method comprises the following steps:
(1) weighing the raw materials according to the weight parts, crushing the materials, and sieving the crushed materials with a 280-mesh sieve;
(2) heating the lubricant to 100 ℃ while stirring for melting uniformly, continuously stirring for 20min while adding the disintegrant, and adding the ivermectin after complete melting for continuous emulsification;
(3) continuously adding albendazole into the mixture obtained in the step (2), and uniformly stirring for 15 min;
(4) continuously adding radix astragali extract and Glycyrrhrizae radix, stirring for 15min, adding stabilizer and correctant, mixing and stirring for 20min to obtain the final product.
Effect verification
The albendazole ivermectin powder obtained in the above examples was tested:
1. and (3) stability test: detecting according to a drug stability experimental method in Chinese veterinary pharmacopoeia; according to the commercial package, the medicine is placed in a medicine stability experiment box with the temperature of 40 +/-2 ℃, the relative humidity of 75 +/-5% and the illumination of 4500 +/-500 LX, and the medicine is respectively sampled for three times to detect.
2. Test evaluation of dispersibility: 2g of prepared albendazole ivermectin powder is added into 1000mL of water to be stirred, the powder is observed to be mixed, stirred and dispersed, the dispersion is fast and uniform and is excellent without stirring, the dispersion is slow and needs to be stirred slightly to be good, the dispersion is slow and is poor due to uneven agglomeration.
The result shows that the albendazole ivermectin powder has good stability and dispersibility and good palatability. After animal experiments, the albendazole ivermectin powder provided by the embodiment of the invention can control the mixed infection of parasites of affected animals within 10 days, is obviously superior to the control effect of albendazole tablets and ivermectin premix, and has the advantages of obvious weight increment and good growth condition.
The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.
Claims (10)
1. An albendazole ivermectin powder, which is characterized in that: the albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 15-20 parts of albendazole, 0.5-1.5 parts of ivermectin, 8-13 parts of lubricant, 70-100 parts of disintegrating agent, 5-8 parts of stabilizer, 2-6 parts of flavoring agent, 3-8 parts of astragalus extract and 3-8 parts of liquorice.
2. Albendazole ivermectin powder according to claim 1, characterized in that: the albendazole ivermectin powder is prepared from the following raw materials in parts by weight: 16-18 parts of albendazole, 0.8-1.2 parts of ivermectin, 10-12 parts of lubricant, 80-90 parts of disintegrating agent, 6-8 parts of stabilizer, 3-5 parts of flavoring agent, 4-6 parts of astragalus extract and 5-7 parts of liquorice.
3. Albendazole ivermectin powder according to claim 2, characterized in that: the lubricant is one or more of magnesium stearate, polyethylene glycol 4000, polyethylene glycol 6000, talcum powder and hydrogenated vegetable oil.
4. Albendazole ivermectin powder according to claim 2, characterized in that: the disintegrating agent is one or more of corn starch, potato starch, sodium carboxymethyl starch, low-substituted cellulose, cross-linked PVP and cross-linked CCNa.
5. Albendazole ivermectin powder according to claim 2, characterized in that: the stabilizer is one or more of sodium citrate and xanthan gum.
6. Albendazole ivermectin powder according to claim 2, characterized in that: the correctant is one or more of sugar powder, saccharin sodium and sucrose.
7. A method for preparing albendazole ivermectin powder as claimed in any one of claims 1 to 6, which is characterized in that: the preparation method comprises the following steps:
(1) weighing the raw materials according to the weight parts, crushing and sieving the materials;
(2) after the lubricant is heated and melted uniformly while stirring, adding the disintegrant while stirring, and adding the ivermectin after complete melting for continuous emulsification;
(3) continuously adding albendazole into the mixture obtained in the step (2), and uniformly stirring;
(4) continuously adding radix astragali extract and Glycyrrhrizae radix, stirring, adding stabilizer and correctant, mixing, and stirring.
8. The method for preparing albendazole ivermectin powder according to claim 7, wherein the method comprises the following steps: and (2) sieving the crushed powder in the step (1) through a sieve of 250-300 meshes.
9. The method for preparing albendazole ivermectin powder according to claim 7, wherein the method comprises the following steps: the heating temperature in the step (2) is 85-105 ℃.
10. The method for preparing albendazole ivermectin powder according to claim 7, wherein the method comprises the following steps: the stirring time in each time in the preparation process is 15-20 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210034051.0A CN114452314A (en) | 2022-01-12 | 2022-01-12 | Albendazole ivermectin powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210034051.0A CN114452314A (en) | 2022-01-12 | 2022-01-12 | Albendazole ivermectin powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114452314A true CN114452314A (en) | 2022-05-10 |
Family
ID=81409164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210034051.0A Pending CN114452314A (en) | 2022-01-12 | 2022-01-12 | Albendazole ivermectin powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114452314A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115227653A (en) * | 2022-07-18 | 2022-10-25 | 河南创鑫生物科技有限公司 | Colistin sulfate soluble powder for treating intestinal infection of livestock and poultry and preparation method thereof |
| CN117771188A (en) * | 2023-12-25 | 2024-03-29 | 中原食品实验室 | Premixing agent containing albendazole and ivermectin and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101848710A (en) * | 2007-11-09 | 2010-09-29 | 英特威国际有限公司 | Anthelmintic combination |
| CN103393706A (en) * | 2013-07-18 | 2013-11-20 | 成都乾坤动物药业有限公司 | Wettable ivermectin albendazole oxide powder |
| CN112618492A (en) * | 2020-12-15 | 2021-04-09 | 四川乾通动物药业有限公司 | Albendazole ivermectin powder and preparation method thereof |
| CN113812522A (en) * | 2021-09-28 | 2021-12-21 | 哈尔滨市联丰饲料有限公司 | Pig feed additive formula and pig feed prepared by same |
-
2022
- 2022-01-12 CN CN202210034051.0A patent/CN114452314A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101848710A (en) * | 2007-11-09 | 2010-09-29 | 英特威国际有限公司 | Anthelmintic combination |
| CN103393706A (en) * | 2013-07-18 | 2013-11-20 | 成都乾坤动物药业有限公司 | Wettable ivermectin albendazole oxide powder |
| CN112618492A (en) * | 2020-12-15 | 2021-04-09 | 四川乾通动物药业有限公司 | Albendazole ivermectin powder and preparation method thereof |
| CN113812522A (en) * | 2021-09-28 | 2021-12-21 | 哈尔滨市联丰饲料有限公司 | Pig feed additive formula and pig feed prepared by same |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115227653A (en) * | 2022-07-18 | 2022-10-25 | 河南创鑫生物科技有限公司 | Colistin sulfate soluble powder for treating intestinal infection of livestock and poultry and preparation method thereof |
| CN117771188A (en) * | 2023-12-25 | 2024-03-29 | 中原食品实验室 | Premixing agent containing albendazole and ivermectin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114452314A (en) | Albendazole ivermectin powder and preparation method thereof | |
| AU2018316531B2 (en) | Oral compositions and the preparation methods thereof | |
| EP0009688B1 (en) | Medical food based on liver powder and process for its preparation | |
| KR20060052935A (en) | Palatable ductile chewable veterinary composition | |
| KR101471922B1 (en) | The method for manufacturing of tea | |
| CN102349608A (en) | Healthcare product combination for clearing and nourishing throat and preparation method thereof | |
| CN101011408A (en) | Animal-used compound preparation for treating parasitic disease in or out of livestock and fowl body and preparation method thereof | |
| CN107693532A (en) | Compound anti-parasitic preparation and preparation method thereof | |
| CN105919954B (en) | A kind of preparation method of the composite tablet containing cordyceps sinensis and American ginseng | |
| CN107595871A (en) | Compound preparation containing ivermectin and preparation method thereof | |
| CN111034863A (en) | Animal solid soft chewing nutritional preparation and preparation method thereof | |
| CN101543298B (en) | Rutin chewing agent and method for preparing same | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN102240310A (en) | Blood-sugar-reducing composition and preparation method thereof | |
| CN108542912A (en) | A kind of albendazole ivermectin microcapsule formulation and preparation method thereof | |
| CN104127389A (en) | Praziquantel chewing tablet for pets and preparation method thereof | |
| CN100509017C (en) | Medicine for treating biliary tract infection and prepn process thereof | |
| KR100959281B1 (en) | Calcium compound fertilized rice of hypoglycemic effect | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| KR102655939B1 (en) | An oral solid formulation comprising rice bran extract with high content | |
| CN112754018A (en) | Vitamin bubble buccal tablet and preparation method thereof | |
| CN105166543A (en) | Cow compound feed and preparation method thereof | |
| CN108114006A (en) | A kind of preparation containing trinosin | |
| CN115671166B (en) | Application of cistanche deserticola in shortening sow labor | |
| CN107753498A (en) | Compound ivermectin tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220510 |